Anne Monks

29.1k citations

103 papers · 24.4k indexed · 8 hit papers · h-index 43

Impact in

Toxicology top 0.02%
- Bioactive Compounds and Antitumor Agents
Organic Chemistry top 0.1%
- Synthesis and biological activity
- Synthesis and Biological Evaluation
- Synthesis and Characterization of Heterocyclic Compounds

Papers in

Oncology 40
- Drug Transport and Resistance Mechanisms 12
- Cancer-related Molecular Pathways 8
Molecular Biology 73
- DNA Repair Mechanisms 11
- Biochemical and Molecular Research 11
- Cancer therapeutics and mechanisms 10
- RNA modifications and cancer 8

Co-authors: Dominic A. Scudiero Philip Skehan David T. Vistica Robert H. Shoemaker jeannette mcmahon M. R. Boyd Susan Kenney James T. Warren
Journals: Cancer Research (8 papers)JNCI Journal of the National Cancer Institute (7 papers)Cancer Chemotherapy and Pharmacology (5 papers)Molecular Cancer Therapeutics (4 papers)Biochemical Pharmacology (4 papers)
Partner nations: United States United Kingdom Malaysia

In The Last Decade

Anne Monks

101 papers receiving 23.6k citations

Hit Papers

8 papers align trajectories log scale

Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. 2000 · 518 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2000 PubMed
1991 JNCI Journal of the National Cancer Institute
1991 PubMed
1990 JNCI Journal of the National Cancer Institute
1990 JNCI Journal of the National Cancer Institute
1989 JNCI Journal of the National Cancer Institute
1988 PubMed
1988 PubMed

Peers

Countries citing papers authored by Anne Monks

Since Specialization

Citations

This map shows the geographic impact of Anne Monks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Monks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Monks more than expected).

Fields of papers citing papers by Anne Monks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Monks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Monks. The network helps show where Anne Monks may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Anne Monks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anne Monks Line = papers co-authored together Anne Monks links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer Cancers ·Mathias Dahlmann, Anne Monks, Erik Harris, Dennis Kobelt, Marc Osterland, Aurelien Mantonnier, Pia Herrmann, Wolfgang Kemmner, Susen Burock, Wolfgang Walther, Robert H. Shoemaker, Ulrike Stein	2021	9
2	Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines Cancer Chemotherapy and Pharmacology ·Mori Tooru, Yingdong Zhao, Anne Monks, Alida Palmisano, Curtis Hose, Beverly A. Teicher, James H. Doroshow, Richard Simon	2019	7
3	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression JNCI Journal of the National Cancer Institute ·Eric C. Polley, Mark W. Kunkel, David M. Evans, Thomas Silvers, René Delosh, Julie Laudeman, Benjamin Ackermann, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Nicole Fer, Dmitriy Sonkin, Gurmeet Kaur, Anne Monks, Shakun Malik, Joel Morris, Beverly A. Teicher	2016	106
4	Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression Molecular Cancer Therapeutics ·Beverly A. Teicher, Eric C. Polley, Mark W. Kunkel, David M. Evans, Thomas Silvers, René Delosh, Julie Laudeman, Benjamin Ackermann, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Anne Monks, Joel Morris	2015	55
5	Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors Cell Cycle ·Sameer H. Issaq, Beverly A. Teicher, Anne Monks	2014	35
6	Cediranib for Metastatic Alveolar Soft Part Sarcoma Journal of Clinical Oncology ·Shivaani Kummar, Deborah Allen, Anne Monks, Eric C. Polley, Curtis Hose, S. Percy Ivy, Barış Türkbey, Scott M. Lawrence, Robert J. Kinders, Peter L. Choyke, Richard Simon, Seth M. Steinberg, James H. Doroshow, Lee J. Helman	2013	156
7	An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). Journal of Clinical Oncology ·Shivaani Kummar, Zhao Yang, Anne Monks, S. Percy Ivy, Barış Türkbey, P L Choyke, Shannon M. Steinberg, In-Suk Kwak, James H. Doroshow, Lee J. Helman	2011	22
8	Development of antiproliferative phenylmaleimides that activate the unfolded protein response Bioorganic & Medicinal Chemistry ·Gyu-Young King, Curtis Hose, Wei Yao, Teresa Kosakowska‐Cholody, David W. Farnsworth, Marzena Dyba, G.T. Lountos, David S. Waugh, Anne Monks, Terrence R. Burke, (unknown)	2010	10
9	Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide] Journal of Pharmacology and Experimental Therapeutics ·Andrew G. Jobson, G.T. Lountos, Philip L. Lorenzi, John Diaz Antillanca, John Connelly, David Cerna, Joseph E. Tropea, Pao Tsin Kuo, Gabriele Zoppoli, Sudhir B. Kondapaka, Guangtao Zhang, Natasha J. Caplen, John H. Cardellina, Stephen Yoo, Anne Monks, Christopher R. Self, David S. Waugh, Robert H. Shoemaker, Yves Pommier	2009	81
10	A sterol mesylate activator of CEBPα signaling induces monocytic differentiation in human leukemia cells in vitro and in vivo Cancer Research ·Erik Harris, Constance J. Glover, Joseph W. Adelsberger, Melinda G. Hollingshead, Ronald L. Felsted, Robert H. Shoemaker, Anne Monks	2006	3
11	Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity Cancer Research ·Dehe Kong, Eun‐Jung Park, Andrew G. Stephen, Maura Calvani, John H. Cardellina, Anne Monks, Robert J. Fisher, Robert H. Shoemaker, Giovanni Melillo	2005	431
12	The Experimental Antitumor Agents Phortress and Doxorubicin are Equiactive Against Human-Derived Breast Carcinoma Xenograft Models Breast Cancer Research and Treatment ·Iduna Fichtner, Anne Monks, Curtis Hose, Malcolm F. G. Stevens, Tracey D. Bradshaw	2004	42
13	Application of High-Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery Current Topics in Medicinal Chemistry ·Robert Shoemaker, Dominic A. Scudiero, Giovanni Melillo, Michael J. Currens, Anne Monks, Alfred A. Rabow, David G. Covell, Edward A. Sausville	2002	69
14	P450 enzyme expression patterns in the NCI human tumor cell line panel. PubMed ·Sylviya Simeonova, J M De Matias, Dominic A. Scudiero, Karen M. Hite, Anne Monks, Edward A. Sausville, David J. Waxman	2001	77
15	Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol Genome biology ·Lloyd T. Lam, Oxana K. Pickeral, A Peng, Andreas Rosenwald, Elaine M. Hurt, Jena M. Giltnane, biade, Hong Zhao, R. Eric Davis, Mei‐Shan Zhang, Larry M. Wahl, S.S. Vanjari, Judy A. Mikovits, Anne Monks, Melinda G. Hollingshead, Edward A. Sausville, Louis M. Staudt	2001	315
16	TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies The Journal of Immunology ·Juan M. Zapata, Maryla Krajewska, Stanisław Krajewski, Shinichi Kitada, Kate Welsh, Anne Monks, Natalie McCloskey, John Gordon, Thomas J. Kipps, Randy D. Gascoyne, Ahmed Shabaik, John C. Reed	2000	118
17	Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel Cancer Chemotherapy and Pharmacology ·Elizabeth S. Woo, Anne Monks, Simon C. Watkins, Saqlain Zaidi, John S. Lazo	1997	32
18	Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration Cancer Chemotherapy and Pharmacology ·Zhirong Zhan, Stefania Scala, Anne Monks, Curtis Hose, Susan E. Bates, Tito Fojo	1997	26
19	New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening JNCI Journal of the National Cancer Institute ·Philip Skehan, Ritsa Storeng, Dominic A. Scudiero, Anne Monks, jeannette mcmahon, David T. Vistica, James T. Warren, Heidi R. Bokesch, Susan Kenney, M. R. Boyd Hit paper breakdown →	1990	8784
20	Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm JNCI Journal of the National Cancer Institute ·Kenneth D. Paull, Robert H. Shoemaker, Louis Hodes, Anne Monks, Dominic A. Scudiero, Larry Rubinstein, Jacqueline Plowman, Michael R. Boyd Hit paper breakdown →	1989	816

About Anne Monks

Anne Monks is a scholar working on Oncology, Molecular Biology, Cancer Research, Clinical Biochemistry and Biotechnology, having authored 103 papers that have together received 24.4k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (12 papers), DNA Repair Mechanisms (11 papers), Biochemical and Molecular Research (11 papers), Cancer therapeutics and mechanisms (10 papers), Computational Drug Discovery Methods (9 papers), HIV/AIDS drug development and treatment (9 papers), Cancer-related Molecular Pathways (8 papers) and RNA modifications and cancer (8 papers). The work is most often cited by research in Toxicology (1.7k citations), Organic Chemistry (6.7k citations), Oncology (5.4k citations), Molecular Biology (12.8k citations) and Biotechnology (1.5k citations). Anne Monks has collaborated with scholars based in United States, United Kingdom and Malaysia. Frequent co-authors include Dominic A. Scudiero, Philip Skehan, David T. Vistica, Robert H. Shoemaker, jeannette mcmahon, M. R. Boyd, Susan Kenney, James T. Warren, Ritsa Storeng and Heidi R. Bokesch. Their work appears in journals such as Cancer Research, JNCI Journal of the National Cancer Institute, Cancer Chemotherapy and Pharmacology, Molecular Cancer Therapeutics and Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact